Crossmark

Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials

Crossref DOI link: https://doi.org/10.1007/s13555-024-01317-7

Published Online: 2025-03-06

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Armstrong, April W. https://orcid.org/0000-0003-0064-8707
Augustin, Matthias

Beaumont, Jennifer L. https://orcid.org/0000-0002-1484-260X
Pham, Tan P. https://orcid.org/0000-0002-5862-5658
Hudgens, Stacie https://orcid.org/0000-0002-7350-1549
Gordon, Kenneth B.

Zhuo, Joe

Becker, Brandon

Zhong, Yichen

Kisa, Renata M.

Banerjee, Subhashis https://orcid.org/0009-0000-1365-5207
Papp, Kim A.
License Information

Text and Data Mining valid from 2025-03-06

Version of Record valid from 2025-03-06
More Information

Article History

First Online: 6 March 2025